Madurai G Ganesan from Atlanta, GA, age 78

Resumes

Vice President

view source

Location:

Atlanta, GA

Industry:

Pharmaceuticals

Work:

Dupont Pharmaceuticals
Vice President

Cofounder And Ceo, Sanja Pharmaceuticals

view source

Location:

Atlanta, GA

Industry:

Pharmaceuticals

Work:

Qs Pharma Feb 1, 2002 - Aug 1, 2010
Founder and President
Sanja Pharmaceuticals Company Feb 1, 2002 - Aug 1, 2010
Cofounder and Ceo, Sanja Pharmaceuticals
Dupont Pharmaceuticals Dec 1, 1996 - Dec 1, 2001
Vice President, Pharmacy R and D
Solvay Pharmaceuticals Sep 1, 1994 - Dec 1, 1996
Director, Product Development
American Cyanamid Mar 1, 1984 - Aug 1, 1994
Scientist and Group Leader and Department Head and Section Manager

Skills:

Product Development
Life Sciences
Technology Transfer
Pharmaceutical Industry
R&D
Fda
Validation
Gmp
Commercialization
Regulatory Affairs

Name / Title

Company / Classification

Phones & Addresses

Madurai Ganesan
President

Q S Pharma Llc
Pharmacies & Drug Stores

3 Chelsea Pkwy #305, Boothwyn, PA 19061
305 Chelsea Pkwy, Boothwyn, PA 19061
(610)4854270, (610)4855933

Madurai Ganesan
Chief Financial Officer, Financial ExecutiveOwner

QS Pharma
Pharmaceuticals · Commercial Physical Research · Commercial Physical Research, Nsk

3 Chelsea Pkwy SUITE #305, Boothwyn, PA 19061
305 Chelsea Pkwy, Boothwyn, PA 19061
(610)4854270, (610)4852249, (610)4855933

Us Patents

Delayed Release Dosage Form
view source
US Patent:

7964215, Jun 21, 2011
Filed:

Nov 27, 2006
Appl. No.:

11/604434
Inventors:

Madurai Gurusamy Ganesan - Newark DE, US
Ramaswamy Balakrishnan - Chadds Ford PA, US
Nutan Kumar Gangrade - Hockessin DE, US
Steven D. Roth - Great Neck NY, US
Assignee:

Emet Pharmaceuticals, LLC - Great Neck NY
International Classification:

A61K 9/22
A61K 9/28
A61K 9/32
US Classification:

424468, 424474, 424482
Abstract:

The present invention is directed to a delayed release pharmaceutical composition in solid dosage form comprising a core comprised of a therapeutically effective amount of drug, e. g. , mesalamine, and a pH sensitive coating comprising a mixture of two different pH sensitive polymers, the first pH sensitive polymer dissolves in an aqueous solution at a pH of about 7 or greater and the second pH sensitive polymer dissolves in an aqueous solution at a pH of about 6 or greater, wherein the weight ratio of the first pH sensitive polymer to the second pH sensitive polymer ranges from about 2:1 to about 4:1 and the percent weight gain resulting from the addition of the pH sensitive coating ranges from about 8% up to and including 15% by weight of the core, including any subcoating.

Intimate Coating Of Ibuprofen With Poloxamers To Enhance Aqueous Dissolution
view source
US Patent:

20060013871, Jan 19, 2006
Filed:

Aug 11, 2005
Appl. No.:

11/201890
Inventors:

Larry Berger - Chadds Ford PA, US
Madurai Ganesan - Newark DE, US
Nutan Gangrade - Hockessin DE, US
Henricus Gommeren - Hockessin DE, US
Torrence Trout - West Chester PA, US
International Classification:

A61K 9/20
A61K 9/36
US Classification:

424464000, 424480000
Abstract:

This invention provides methods for enhancing the dissolution rate of Ibuprofen. More particularly, the invention provides a process for enhancing the solubility of Ibuprofen by intimately coating Ibuprofen particles with a Poloxamer. The invention also provides for a composition comprising a solid dosage form of Ibuprofen, wherein the surfaces of Ibuprofen particles have been intimately coated with a Poloxamer; a composition comprising a fast onset, solid dosage form of Ibuprofen; and a composition comprising Ibuprofen particles intimately coated with a Poloxamer.